Intravenous to Subcutaneous Drug Repositioning Market Size, Share & Growth Graph by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Intravenous to Subcutaneous Drug Repositioning Market Size Analysis

Global Intravenous to Subcutaneous Drug Repositioning Market Introduction
By Product
1. Introduction
  1. Product By Value
2. Devices
  1. By Value
  2. Wearable SC Injectors
    1. Wearable SC Injectors By Value
  3. Wearable SC Infusers
    1. Wearable SC Infusers By Value
3. Drugs
  1. By Value
  2. Cancer Drugs
    1. Cancer Drugs By Value
  3. Blood Factors
    1. Blood Factors By Value
  4. Immunoglobulin G
    1. Immunoglobulin G By Value
  5. Antibiotics
    1. Antibiotics By Value
  6. Remodulin
    1. Remodulin By Value
  7. Others
    1. Others By Value
By Therapeutic Indication
1. Introduction
  1. Therapeutic Indication By Value
2. Cardiology
  1. By Value
3. Oncology
  1. By Value
4. Pulmonary Arterial Hypertension
  1. By Value
5. Hematology
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Facilities
  1. By Value
4. Others
  1. By Value

North America Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Devices
  1. By Value
  2. Wearable SC Injectors
    1. Wearable SC Injectors By Value
  3. Wearable SC Infusers
    1. Wearable SC Infusers By Value
3. Drugs
  1. By Value
  2. Cancer Drugs
    1. Cancer Drugs By Value
  3. Blood Factors
    1. Blood Factors By Value
  4. Immunoglobulin G
    1. Immunoglobulin G By Value
  5. Antibiotics
    1. Antibiotics By Value
  6. Remodulin
    1. Remodulin By Value
  7. Others
    1. Others By Value
By Therapeutic Indication
1. Introduction
  1. Therapeutic Indication By Value
2. Cardiology
  1. By Value
3. Oncology
  1. By Value
4. Pulmonary Arterial Hypertension
  1. By Value
5. Hematology
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Facilities
  1. By Value
4. Others
  1. By Value
U.S.
1. By Product
  1. Introduction
    1. Product By Value
  2. Devices
    1. By Value
    2. Wearable SC Injectors
      1. Wearable SC Injectors By Value
    3. Wearable SC Infusers
      1. Wearable SC Infusers By Value
  3. Drugs
    1. By Value
    2. Cancer Drugs
      1. Cancer Drugs By Value
    3. Blood Factors
      1. Blood Factors By Value
    4. Immunoglobulin G
      1. Immunoglobulin G By Value
    5. Antibiotics
      1. Antibiotics By Value
    6. Remodulin
      1. Remodulin By Value
    7. Others
      1. Others By Value
2. By Therapeutic Indication
  1. Introduction
    1. Therapeutic Indication By Value
  2. Cardiology
    1. By Value
  3. Oncology
    1. By Value
  4. Pulmonary Arterial Hypertension
    1. By Value
  5. Hematology
    1. By Value
  6. Others
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research Facilities
    1. By Value
  4. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Devices
  1. By Value
  2. Wearable SC Injectors
    1. Wearable SC Injectors By Value
  3. Wearable SC Infusers
    1. Wearable SC Infusers By Value
3. Drugs
  1. By Value
  2. Cancer Drugs
    1. Cancer Drugs By Value
  3. Blood Factors
    1. Blood Factors By Value
  4. Immunoglobulin G
    1. Immunoglobulin G By Value
  5. Antibiotics
    1. Antibiotics By Value
  6. Remodulin
    1. Remodulin By Value
  7. Others
    1. Others By Value
By Therapeutic Indication
1. Introduction
  1. Therapeutic Indication By Value
2. Cardiology
  1. By Value
3. Oncology
  1. By Value
4. Pulmonary Arterial Hypertension
  1. By Value
5. Hematology
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Facilities
  1. By Value
4. Others
  1. By Value
U.K.
1. By Product
  1. Introduction
    1. Product By Value
  2. Devices
    1. By Value
    2. Wearable SC Injectors
      1. Wearable SC Injectors By Value
    3. Wearable SC Infusers
      1. Wearable SC Infusers By Value
  3. Drugs
    1. By Value
    2. Cancer Drugs
      1. Cancer Drugs By Value
    3. Blood Factors
      1. Blood Factors By Value
    4. Immunoglobulin G
      1. Immunoglobulin G By Value
    5. Antibiotics
      1. Antibiotics By Value
    6. Remodulin
      1. Remodulin By Value
    7. Others
      1. Others By Value
2. By Therapeutic Indication
  1. Introduction
    1. Therapeutic Indication By Value
  2. Cardiology
    1. By Value
  3. Oncology
    1. By Value
  4. Pulmonary Arterial Hypertension
    1. By Value
  5. Hematology
    1. By Value
  6. Others
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research Facilities
    1. By Value
  4. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Devices
  1. By Value
  2. Wearable SC Injectors
    1. Wearable SC Injectors By Value
  3. Wearable SC Infusers
    1. Wearable SC Infusers By Value
3. Drugs
  1. By Value
  2. Cancer Drugs
    1. Cancer Drugs By Value
  3. Blood Factors
    1. Blood Factors By Value
  4. Immunoglobulin G
    1. Immunoglobulin G By Value
  5. Antibiotics
    1. Antibiotics By Value
  6. Remodulin
    1. Remodulin By Value
  7. Others
    1. Others By Value
By Therapeutic Indication
1. Introduction
  1. Therapeutic Indication By Value
2. Cardiology
  1. By Value
3. Oncology
  1. By Value
4. Pulmonary Arterial Hypertension
  1. By Value
5. Hematology
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Facilities
  1. By Value
4. Others
  1. By Value
China
1. By Product
  1. Introduction
    1. Product By Value
  2. Devices
    1. By Value
    2. Wearable SC Injectors
      1. Wearable SC Injectors By Value
    3. Wearable SC Infusers
      1. Wearable SC Infusers By Value
  3. Drugs
    1. By Value
    2. Cancer Drugs
      1. Cancer Drugs By Value
    3. Blood Factors
      1. Blood Factors By Value
    4. Immunoglobulin G
      1. Immunoglobulin G By Value
    5. Antibiotics
      1. Antibiotics By Value
    6. Remodulin
      1. Remodulin By Value
    7. Others
      1. Others By Value
2. By Therapeutic Indication
  1. Introduction
    1. Therapeutic Indication By Value
  2. Cardiology
    1. By Value
  3. Oncology
    1. By Value
  4. Pulmonary Arterial Hypertension
    1. By Value
  5. Hematology
    1. By Value
  6. Others
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research Facilities
    1. By Value
  4. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Devices
  1. By Value
  2. Wearable SC Injectors
    1. Wearable SC Injectors By Value
  3. Wearable SC Infusers
    1. Wearable SC Infusers By Value
3. Drugs
  1. By Value
  2. Cancer Drugs
    1. Cancer Drugs By Value
  3. Blood Factors
    1. Blood Factors By Value
  4. Immunoglobulin G
    1. Immunoglobulin G By Value
  5. Antibiotics
    1. Antibiotics By Value
  6. Remodulin
    1. Remodulin By Value
  7. Others
    1. Others By Value
By Therapeutic Indication
1. Introduction
  1. Therapeutic Indication By Value
2. Cardiology
  1. By Value
3. Oncology
  1. By Value
4. Pulmonary Arterial Hypertension
  1. By Value
5. Hematology
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Facilities
  1. By Value
4. Others
  1. By Value
UAE
1. By Product
  1. Introduction
    1. Product By Value
  2. Devices
    1. By Value
    2. Wearable SC Injectors
      1. Wearable SC Injectors By Value
    3. Wearable SC Infusers
      1. Wearable SC Infusers By Value
  3. Drugs
    1. By Value
    2. Cancer Drugs
      1. Cancer Drugs By Value
    3. Blood Factors
      1. Blood Factors By Value
    4. Immunoglobulin G
      1. Immunoglobulin G By Value
    5. Antibiotics
      1. Antibiotics By Value
    6. Remodulin
      1. Remodulin By Value
    7. Others
      1. Others By Value
2. By Therapeutic Indication
  1. Introduction
    1. Therapeutic Indication By Value
  2. Cardiology
    1. By Value
  3. Oncology
    1. By Value
  4. Pulmonary Arterial Hypertension
    1. By Value
  5. Hematology
    1. By Value
  6. Others
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research Facilities
    1. By Value
  4. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Devices
  1. By Value
  2. Wearable SC Injectors
    1. Wearable SC Injectors By Value
  3. Wearable SC Infusers
    1. Wearable SC Infusers By Value
3. Drugs
  1. By Value
  2. Cancer Drugs
    1. Cancer Drugs By Value
  3. Blood Factors
    1. Blood Factors By Value
  4. Immunoglobulin G
    1. Immunoglobulin G By Value
  5. Antibiotics
    1. Antibiotics By Value
  6. Remodulin
    1. Remodulin By Value
  7. Others
    1. Others By Value
By Therapeutic Indication
1. Introduction
  1. Therapeutic Indication By Value
2. Cardiology
  1. By Value
3. Oncology
  1. By Value
4. Pulmonary Arterial Hypertension
  1. By Value
5. Hematology
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research Facilities
  1. By Value
4. Others
  1. By Value
Brazil
1. By Product
  1. Introduction
    1. Product By Value
  2. Devices
    1. By Value
    2. Wearable SC Injectors
      1. Wearable SC Injectors By Value
    3. Wearable SC Infusers
      1. Wearable SC Infusers By Value
  3. Drugs
    1. By Value
    2. Cancer Drugs
      1. Cancer Drugs By Value
    3. Blood Factors
      1. Blood Factors By Value
    4. Immunoglobulin G
      1. Immunoglobulin G By Value
    5. Antibiotics
      1. Antibiotics By Value
    6. Remodulin
      1. Remodulin By Value
    7. Others
      1. Others By Value
2. By Therapeutic Indication
  1. Introduction
    1. Therapeutic Indication By Value
  2. Cardiology
    1. By Value
  3. Oncology
    1. By Value
  4. Pulmonary Arterial Hypertension
    1. By Value
  5. Hematology
    1. By Value
  6. Others
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research Facilities
    1. By Value
  4. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Intravenous to Subcutaneous Drug Repositioning Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Baxter International
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
United Therapeutics
SteadyMed Therapeutics
CSL Behring
Hoffmann-La Roche Ltd.
Braun Melsungen AG
Fresenius SE & Co. KGaA
Grifols, S.A.
ICU Medical, Inc.
Pfizer Inc. (including Hospira division)
Halozyme Therapeutics, Inc.
Ascendis Pharma A/S
Xeris Biopharma Holdings, Inc.
Alteogen Inc.
Merck KGgA

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment